Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC0245 plus irinotecan in relapsed or refractory extensive-stage small cell lung cancer
CTR20223363Phase 2Suspended
- Sponsor
- Zhikang Hongyi
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SC0245, irinotecan, sponsored by Zhikang Hongyi. Started Feb 2023; status: suspended.
02
Drugs
SC0245irinotecan
Beyond the preview
Go deeper on CTR20223363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223363.